{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:25:56Z","timestamp":1791404756217,"version":"4.3.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sigmund Freud Privatuniversit\u00e4t Wien"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>In a\u00a0retrospective study, we analyzed the prevalence of elevated C\u2011reactive protein (CRP) serum levels in 148\u00a0patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with laboratory features. Normal, up to 10-fold, and more than 10-fold elevated CRP levels were found in 18%, 59%, and 23% of CMML patients, respectively. Using the CRP cutoff value of 10\u202fmg\/L of the widely used Glasgow score, high CRP values were associated with inferior survival (13 vs. 39\u00a0months, <jats:italic>p<\/jats:italic>\u202f=\u20090.014), which retained prognostic significance in multivariate analysis. High CRP values were associated with lower hemoglobin levels. The survival difference between patients with normal (&lt;\u202f5\u202fmg\/L) and elevated CRP levels persisted after exclusion of patients with clinical infection. These findings indicate that in CMML patients, the presence of an acute-phase reaction is associated with a\u00a0poor outcome, independent of clinical infection.<\/jats:p>","DOI":"10.1007\/s10354-022-00981-8","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T09:08:54Z","timestamp":1669626534000},"page":"15-20","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Significance of C-reactive protein in patients with chronic myelomonocytic leukemia","Bedeutung des C-reaktiven Proteins bei Patienten mit chronischer myelomonozyt\u00e4rer Leuk\u00e4mie"],"prefix":"10.1007","volume":"173","author":[{"given":"Jian","family":"Liang-Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1921-7034","authenticated-orcid":false,"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"issue":"2","key":"981_CR1","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett\u00a0JM, Catovsky\u00a0D, Daniel\u00a0MT, et\u00a0al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189\u201399.","journal-title":"Br J Haematol"},{"issue":"7","key":"981_CR2","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman\u00a0JW, Harris\u00a0NL, Brunning\u00a0RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292\u2013302.","journal-title":"Blood"},{"issue":"5","key":"981_CR3","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman\u00a0JW, Thiele\u00a0J, Arber\u00a0DA, et\u00a0al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"20","key":"981_CR4","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0R, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"3","key":"981_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood.V99.3.840","volume":"99","author":"F Onida","year":"2002","unstructured":"Onida\u00a0F, Kantarjian\u00a0HM, Smith\u00a0TL, et\u00a0al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a\u00a0retrospective analysis of 213\u00a0patients. Blood. 2002;99(3):840\u20139.","journal-title":"Blood"},{"issue":"7","key":"981_CR6","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/leu.2013.88","volume":"27","author":"MM Patnaik","year":"2013","unstructured":"Patnaik\u00a0MM, Padron\u00a0E, LaBorde\u00a0RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013;27(7):1504\u201310.","journal-title":"Leukemia"},{"issue":"19","key":"981_CR7","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson\u00a0R, Kosmider\u00a0O, Renneville\u00a0A, et\u00a0al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J\u00a0Clin Oncol. 2013;31(19):2428\u201336.","journal-title":"J Clin Oncol"},{"issue":"10","key":"981_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena\u00a0C, Gall\u00ec\u00a0A, Such\u00a0E, et\u00a0al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128(10):1408\u201317.","journal-title":"Blood"},{"issue":"2","key":"981_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/ejh.13647","volume":"107","author":"S Machherndl-Spandl","year":"2021","unstructured":"Machherndl-Spandl\u00a0S, J\u00e4ger\u00a0E, Barna\u00a0A, et al. Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia. Eur J Haematol. 2021;107(2):265\u201374.","journal-title":"Eur J Haematol"},{"issue":"9","key":"981_CR10","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","volume":"6","author":"P Fenaux","year":"1988","unstructured":"Fenaux\u00a0P, Beuscart\u00a0R, Lai\u00a0JL, et\u00a0al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107\u00a0cases. J\u00a0Clin Oncol. 1988;6(9):1417\u201324.","journal-title":"J Clin Oncol"},{"issue":"2","key":"981_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1182\/blood-2002-01-0330","volume":"100","author":"U Germing","year":"2002","unstructured":"Germing\u00a0U, Strupp\u00a0C, Aivado\u00a0M, et\u00a0al. New prognostic parameters for chronic myelomonocytic leukemia. Blood. 2002;100(2):731\u20132. author reply 732\u2013733.","journal-title":"Blood"},{"issue":"11","key":"981_CR12","first-page":"766","volume":"4","author":"AM Storniolo","year":"1990","unstructured":"Storniolo\u00a0AM, Moloney\u00a0WC, Rosenthal\u00a0DS, et\u00a0al. Chronic myelomonocytic leukemia. Leukemia. 1990;4(11):766\u201370.","journal-title":"Leukemia"},{"issue":"12","key":"981_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","volume":"38","author":"E Schuler","year":"2014","unstructured":"Schuler\u00a0E, Schroeder\u00a0M, Neukirchen\u00a0J, et\u00a0al. Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias. Leuk Res. 2014;38(12):1413\u20139.","journal-title":"Leuk Res"},{"issue":"10","key":"981_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","volume":"64","author":"A Tefferi","year":"1989","unstructured":"Tefferi\u00a0A, Hoagland\u00a0HC, Therneau\u00a0TM, et\u00a0al. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc. 1989;64(10):1246\u201354.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"981_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2141.1988.tb04173.x","volume":"68","author":"A Worsley","year":"1988","unstructured":"Worsley\u00a0A, Oscier\u00a0DG, Stevens\u00a0J, et\u00a0al. Prognostic features of chronic myelomonocytic leukaemia: a\u00a0modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988;68(1):17\u201321.","journal-title":"Br J Haematol"},{"issue":"3","key":"981_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2010.030957","volume":"96","author":"E Such","year":"2011","unstructured":"Such\u00a0E, Cervera\u00a0J, Costa\u00a0D, et\u00a0al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96(3):375\u201383.","journal-title":"Haematologica"},{"issue":"15","key":"981_CR17","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such\u00a0E, Germing\u00a0U, Malcovati\u00a0L, et\u00a0al. Development and validation of a\u00a0prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121(15):3005\u201315.","journal-title":"Blood"},{"issue":"12","key":"981_CR18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.23846","volume":"89","author":"EA Wassie","year":"2014","unstructured":"Wassie\u00a0EA, Itzykson\u00a0R, Lasho\u00a0TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a\u00a0Mayo Clinic-French Consortium Study. Am J Hematol. 2014;89(12):1111\u20135.","journal-title":"Am J Hematol"},{"issue":"6","key":"981_CR19","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","volume":"2","author":"R Itzykson","year":"2018","unstructured":"Itzykson\u00a0R, Fenaux\u00a0P, Bowen\u00a0D, et\u00a0al. Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European hematology association and the European leukemianet. Hemasphere. 2018;2(6):e150.","journal-title":"Hemasphere"},{"issue":"11","key":"981_CR20","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1038\/leu.2014.125","volume":"28","author":"MM Patnaik","year":"2014","unstructured":"Patnaik\u00a0MM, Itzykson\u00a0R, Lasho\u00a0TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a\u00a0two-center study of 466\u00a0patients. Leukemia. 2014;28(11):2206\u201312.","journal-title":"Leukemia"},{"issue":"7","key":"981_CR21","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1038\/bcj.2015.53","volume":"5","author":"E Padron","year":"2015","unstructured":"Padron\u00a0E, Garcia-Manero\u00a0G, Patnaik\u00a0MM, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a\u00a0need for novel prognostication strategies. Blood Cancer\u00a0J. 2015;5(7):e333.","journal-title":"Blood Cancer J"},{"key":"981_CR22","first-page":"345","volume":"27","author":"H Gewurz","year":"1982","unstructured":"Gewurz\u00a0H, Mold\u00a0C, Siegel\u00a0J, et al. C\u2011reactive protein and the acute phase response. Adv Intern Med. 1982;27:345\u201372.","journal-title":"Adv Intern Med"},{"issue":"17\u201318","key":"981_CR23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s00508-019-1526-1","volume":"131","author":"K Geissler","year":"2019","unstructured":"Geissler\u00a0K, J\u00e4ger\u00a0E, Barna\u00a0A, et al. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): a representative and useful real-life data source for further biomedical research. Wien Klin Wochenschr. 2019;131(17\u201318):410\u20138.","journal-title":"Wien Klin Wochenschr"},{"issue":"7","key":"981_CR24","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2013.100","volume":"27","author":"R Itzykson","year":"2013","unstructured":"Itzykson\u00a0R, Solary\u00a0E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27(7):1441\u201350.","journal-title":"Leukemia"},{"issue":"4","key":"981_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/ijlh.13212","volume":"42","author":"K Foucar","year":"2020","unstructured":"Foucar\u00a0K, Hsi\u00a0ED, Wang\u00a0SA, et\u00a0al. Concordance among hematopathologists in classifying blasts plus promonocytes: a bone marrow pathology group study. Int J Lab Hem. 2020;42(4):418\u201322.","journal-title":"Int J Lab Hem"},{"issue":"4","key":"981_CR26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/sj.bjc.6606087","volume":"104","author":"MJ Proctor","year":"2011","unstructured":"Proctor\u00a0MJ, Morrison\u00a0DS, Talwar\u00a0D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a\u00a0Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726\u201334.","journal-title":"Br J Cancer"},{"issue":"10","key":"981_CR27","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/leu.2013.207","volume":"27","author":"T Barbui","year":"2013","unstructured":"Barbui\u00a0T, Carobbio\u00a0A, Finazzi\u00a0G, et al. Elevated C\u2011reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia. 2013;27(10):2084\u20136.","journal-title":"Leukemia"},{"issue":"12","key":"981_CR28","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1080\/10428194.2020.1789627","volume":"61","author":"M Lucijanic","year":"2020","unstructured":"Lucijanic\u00a0M, Galusic\u00a0D, Krecak\u00a0I, et\u00a0al. C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis. Leuk Lymphoma. 2020;61(12):2969\u201374.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"981_CR29","doi-asserted-by":"publisher","first-page":"512","DOI":"10.9738\/INTSURG-D-13-00118.1","volume":"99","author":"T Nozoe","year":"2014","unstructured":"Nozoe\u00a0T, Matono\u00a0R, Ijichi\u00a0H, et\u00a0al. Glasgow prognostic score (GPS) can be a\u00a0useful indicator to determine prognosis of patients with colorectal carcinoma. Int Surg. 2014;99(5):512\u20137.","journal-title":"Int Surg"},{"issue":"14","key":"981_CR30","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch\u00a0HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a\u00a0trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119(14):3219\u201325.","journal-title":"Blood"},{"issue":"1","key":"981_CR31","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/s41467-020-15497-1","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh\u00a0S, Osswald\u00a0L, Saller\u00a0BS, et\u00a0al. Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. Nat Commun. 2020;11(1):1659.","journal-title":"Nat Commun"},{"key":"981_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx187","author":"S Khozin","year":"2017","unstructured":"Khozin\u00a0S, Blumenthal\u00a0GM, Pazdur\u00a0R. Real-world data for clinical evidence generation in oncology. J\u00a0Natl Cancer Inst. 2017; https:\/\/doi.org\/10.1093\/jnci\/djx187.","journal-title":"J Natl Cancer Inst"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-022-00981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10354-022-00981-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-022-00981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T07:17:12Z","timestamp":1674631032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10354-022-00981-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":32,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["981"],"URL":"https:\/\/doi.org\/10.1007\/s10354-022-00981-8","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"20 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Liang-Fonseca and K.\u00a0Geissler declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}